TotalCareMedical.com Health Team

By TotalCareMedical.com Health Team

Please note: This comparison covers three compounded GLP-1 telehealth platforms reviewed editorially by TotalCareMedical.com. All three operate in the compounded medication category, which the FDA's April 30, 2026 503B proposal directly affects. Compounded medications are not FDA-approved finished drugs. This article is educational, not medical advice. Consult a licensed clinician for any prescribing decision.

Three compounded GLP-1 telehealth platforms have featured in our editorial coverage: Novi, SynergyRx, and TeleHealth Med. Each operates the same general category — connect adult patients with US-licensed clinicians, prescribe compounded semaglutide or tirzepatide when medically appropriate, ship from a partner pharmacy network. The differences sit in price points, transparency, commitment structures, and how each platform is positioned to weather the regulatory environment that took shape on April 30, 2026.

This isn't a ranking exercise. It's a side-by-side read of what's published, where each platform is specific, and where each leaves diligence questions for the prospective patient to ask. The honest-broker frame: the platform that fits your situation depends on what you value, not on which has the most aggressive marketing.

Pricing — Headline Numbers

Novi publishes the lowest entry-tier price for compounded semaglutide at $174 per month, with compounded tirzepatide starting at $283. The marketing emphasizes affordability and explicitly positions the platform as “the most affordable” in its category. Free 2-day shipping is included.

SynergyRx publishes compounded semaglutide injections starting at $199, compounded tirzepatide injections at $349, oral compounded semaglutide tablets at $299, and oral compounded tirzepatide tablets at $399. Brand-name medications are also available at significantly higher price points (Wegovy from $947, Mounjaro from $947, Ozempic from $499). The platform's headline is $299.

TeleHealth Med's published headline is $147 for general GLP-1 weight management access. Specific dose-tier breakdowns aren't as detailed in the platform's published materials, and patients confirm specific medication pricing during consultation.

The starting-price spread across the three platforms isn't dramatic. The structural differences in what's included, commitment terms, and pharmacy network transparency matter more than the entry price. For Novi-specific pricing detail including the 3-month commitment math, see our Novi cost analysis.

Pharmacy Network Disclosure — A Diligence Dimension That Now Matters More

This is the dimension where the three platforms diverge sharply.

SynergyRx publicly names its pharmacy partners: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx. The platform's published Medical Team identifies the prescribing physician group (Lion MD), led by Dr. Ana Lisa Carr, MD (NPI 1689841744) and Dr. Kelly Tenbrink, MD (NPI 1346482684). That's an unusual level of disclosure for the category and gives prospective patients direct visibility into where their medication originates.

Novi describes “trusted, licensed U.S. pharmacies” in its published terms but does not name specific pharmacy partners or disclose 503A vs 503B status. The clinical team is publicly identified — Daniel Funsch, MD; Michael Wasef, MD; Takashi Nakamura, MD; and several nurse practitioners — which is meaningful, but the pharmacy network remains opaque without direct inquiry.

TeleHealth Med similarly references licensed US pharmacies in its published materials without naming specific partners.

Why this dimension matters more in May 2026 than it did three months ago: the FDA's April 30, 2026 proposal targets 503B outsourcing facility compounding of semaglutide, tirzepatide, and liraglutide specifically. A platform whose pharmacy network operates primarily under 503A (state-licensed patient-specific compounding) is in a different regulatory position than a platform reliant on 503B outsourcing facilities. Without disclosure, that question can only be answered by direct inquiry to customer support. The full mechanics of the regulatory framework are covered in our Novi compounded vs brand analysis.

This isn't a knock against Novi or TeleHealth Med specifically. It's a category observation. Pharmacy disclosure is becoming a more important consumer signal than it was during the 2022–2024 shortage period. Platforms that proactively disclose are differentiating.

Medication Options

SynergyRx offers the broadest published medication menu of the three: compounded semaglutide injection, compounded tirzepatide injection, oral compounded semaglutide tablets, oral compounded tirzepatide tablets, and brand-name Wegovy, Mounjaro, and Ozempic. The brand-name access matters for patients who want or need an FDA-approved finished product but prefer telehealth convenience.

Novi offers compounded semaglutide and compounded tirzepatide as its two core options. The marketing clearly positions these as the affordable cash-pay path. The platform's terms acknowledge that branded options may have different reimbursement potential, but compounded options are the focus.

TeleHealth Med offers compounded semaglutide and tirzepatide as its core GLP-1 menu, with general weight management consultation framing.

For a patient whose path-of-least-resistance is compounded GLP-1 cash-pay, all three platforms can deliver. For a patient who specifically wants brand-name access through telehealth or the option to switch between compounded and brand-name during treatment, SynergyRx has the broader published menu.

Commitment Terms and Refund Policy

Novi's published commitment is 3 months minimum, with all three months charged at time of purchase and non-refundable except for pre-prescription medical ineligibility. Cancellation requires 15 days' notice before the next monthly processing date, after the 3-month commitment is completed. Once a prescription is dispensed or shipped, no refunds. We cover Novi's specific cancellation mechanics in the Novi side effects and cancellation policy review.

SynergyRx and TeleHealth Med commitment structures vary by program tier and aren't uniformly disclosed in the same level of detail in their published materials. Across the compounded-GLP-1 telehealth category, multi-month commitments are common. Patients should confirm specific commitment terms directly with each platform before paying.

The category norm — multi-month commitments with strict refund terms after dispensing — exists because compounding pharmacy partnerships involve upfront sourcing costs that platforms recoup over the full subscription window. That's a defensible business reason. It's also a consumer factor that should be priced into the decision before signing up.

Editorial Tone and Marketing Posture

Each platform's marketing tone is worth reading.

Novi's marketing is the most aggressive on outcome claims — “lose up to 24% of your body weight,” prominently featured testimonial figures (52 lbs, 130 lbs, 33 lbs, etc.), and “Join 100,000+ PATIENTS” framing. The “up to 24%” exceeds the upper end of typical brand-name FDA-approved trial reporting (the SURMOUNT trials of brand-name tirzepatide 15 mg reported approximately 20.9% over 72 weeks). The number is presented as marketing aspiration, not as Novi-specific outcome data. It should be read accordingly.

SynergyRx's marketing is more clinical in tone, with explicit acknowledgment of compounding-versus-brand-name distinctions and trial-data scope caveats throughout the platform's published descriptions. The marketing is professional but less promotional than Novi's.

TeleHealth Med's marketing is broad-based and educational rather than outcome-focused, with general telehealth-category framing rather than aggressive efficacy positioning.

None of these tones is a quality signal in either direction. They reflect each platform's positioning. Aggressive marketing isn't a disqualification — it's a signal that the prospective patient should ground their expectations in the underlying peer-reviewed data, not in the marketing copy.

Clinical Process

The intake process across the three platforms is structurally similar. An online medical questionnaire collects health history, BMI, medications, contraindications, and goals. A US-licensed clinician reviews the submission. A virtual consultation may be scheduled if the clinician determines additional information is needed. If treatment is medically appropriate, a prescription is issued and shipped from a partner pharmacy.

The screening rigor varies in detail but not in fundamental approach. All three platforms screen for the standard GLP-1 contraindications: medullary thyroid carcinoma history, MEN2 syndrome, pancreatitis history, severe gastrointestinal disorders, pregnancy. The thoroughness of the screening depends, in all three cases, on accurate patient self-disclosure.

The follow-up structure is similar across the three. Provider check-ins, dose adjustment guidance, and ongoing communication are included in all three platforms' published program descriptions. Specific cadence — weekly, monthly, on-demand — varies and should be confirmed during sign-up.

The Regulatory Inflection Point

All three platforms operate inside the compounded GLP-1 telehealth category that the FDA's April 30, 2026 proposal directly affects. The proposal would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — closing the 503B pathway for bulk compounding of these molecules. The public comment period closes June 29, 2026.

How each platform navigates the post-June-29 environment will become a meaningful differentiator. Platforms that have already cultivated 503A pharmacy relationships are positioned differently than platforms reliant on 503B outsourcing facility supply. Platforms that already offer brand-name access alongside compounded options have a hedge that pure-compounded platforms don't. Platforms that proactively disclose pharmacy network structure give prospective patients the information needed to evaluate stability.

For a comprehensive framework on what to ask before committing to any platform in this category, see our core Novi review.

Side-by-Side Summary

Pricing entry tier: TeleHealth Med ($147 general entry) — Novi ($174 compounded semaglutide) — SynergyRx ($199 compounded semaglutide). Novi offers the lowest dedicated semaglutide entry price; SynergyRx offers the broadest medication menu including brand-name options at higher price points.

Pharmacy disclosure: SynergyRx publicly names four pharmacy partners. Novi and TeleHealth Med describe licensed US pharmacies without naming specific partners. In the post-April-30 regulatory environment, this dimension carries more weight than it did previously.

Medication breadth: SynergyRx offers compounded semaglutide and tirzepatide in injection and oral tablet form, plus brand-name Wegovy, Mounjaro, and Ozempic. Novi offers compounded semaglutide and tirzepatide. TeleHealth Med offers compounded semaglutide and tirzepatide.

Commitment structure: Novi explicitly publishes a 3-month minimum commitment with strict refund terms. SynergyRx and TeleHealth Med commitment structures vary by program tier and warrant direct inquiry.

Marketing posture: Novi most aggressive on outcome claims; SynergyRx more clinical/professional; TeleHealth Med educational/broad.

Clinical team disclosure: All three publicly identify their clinical team. SynergyRx additionally publishes provider NPI numbers, which is the most rigorous disclosure level of the three.

Who Each Platform Likely Fits Best

Novi may fit prospective patients who prioritize the lowest dedicated compounded-semaglutide entry price, who can comfortably absorb a 3-month financial commitment regardless of response to medication, and who are willing to ask the pharmacy-network diligence question before signing up. The “up to 24%” outcome marketing should be read with appropriate skepticism — but the underlying program structure is consistent with category norms.

SynergyRx may fit prospective patients who prioritize pharmacy-network transparency, who want the option to switch between compounded and brand-name during treatment, who appreciate explicit clinical-tone marketing with regulatory caveats, or who specifically want the broader medication menu. The price point is modestly higher than Novi's at the entry tier; the disclosure level is meaningfully higher.

TeleHealth Med may fit prospective patients who prioritize the lowest general entry price and a more educational platform tone, with the understanding that pharmacy network detail and commitment structure require direct inquiry to clarify.

None of these is universally “best.” The right platform depends on what the prospective patient values and what they are willing to verify before paying.

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Please note: This article covers documented side effects of GLP-1 receptor agonists and Novi's published cancellation and refund policy. It is educational, not medical advice. Side effects vary among individuals, and any patient experiencing symptoms should communicate directly with their prescriber. Compounded medications are not FDA-approved finished drugs.

Two facts about a compounded GLP-1 telehealth subscription are worth knowing in the same breath. First: GLP-1 medications work in part because they cause gastrointestinal side effects — that's the mechanism, slowed gastric emptying and altered appetite signaling, doing its job. Second: once Novi dispenses a prescription, refunds aren't available, regardless of whether the patient tolerates the medication.

Those two facts intersect for prospective patients. The decision to start treatment is also a financial commitment to the 3-month subscription window, with limited exit pathways for tolerability reasons. This article covers what side effects to actually expect from the medications Novi prescribes, what Novi's clinical safety mechanics look like, and exactly what the cancellation and refund terms say.

The Side Effect Profile of GLP-1 Medications — What's Actually Documented

The published clinical trial data and post-marketing surveillance for semaglutide and tirzepatide describe a fairly consistent side effect profile across studied populations. The 2026 systematic review aggregating 22 randomized controlled trials across 41,757 individuals reported the following frequency ranges for GLP-1 receptor agonists versus placebo:

Nausea — 14% to 28% of trial participants on GLP-1 medications, versus 5% to 10% on placebo. This is the most commonly reported side effect across the class and tends to be most pronounced in the first weeks of treatment and during dose escalation.

Vomiting — 6% to 12% on GLP-1 medications versus 2% to 4% on placebo. Less common than nausea but a significant minority experience it, particularly at higher doses.

Diarrhea — 8% to 20% versus 4% to 7%. Highly variable across trials and individuals.

Constipation — Reported in clinical trials at meaningful frequency. Often results from slowed gastric and intestinal motility, which is part of the medication's mechanism.

Decreased appetite — This is, technically, the desired effect. It also represents a significant change from baseline that some patients find uncomfortable, particularly if it interferes with adequate hydration or nutrition.

For context: the trials of brand-name tirzepatide and brand-name semaglutide found that, despite these effects, the risk of pancreatitis and serious adverse events remained comparable to placebo. The class is not characterized by a high rate of severe events. It is characterized by a high rate of moderate gastrointestinal effects, particularly during titration.

One interesting comparative finding from preclinical research: dual GLP-1/GIP agonists like tirzepatide may be associated with somewhat fewer gastrointestinal adverse events than equipotent doses of pure GLP-1 agonists like semaglutide, with similar weight-loss effects. The clinical implication for individual patients is uncertain — both molecules have substantial side effect rates in real-world use.

How Novi's Screening Process Works

Per Novi's published intake description, the medical questionnaire collects current weight and BMI, medical history, existing medications, prior weight-loss efforts, and lifestyle context. A US-licensed clinician reviews the submission. If the clinician determines additional information is needed, a virtual visit may be scheduled. If the clinician determines treatment is medically appropriate, a prescription is issued.

The platform's published clinical team — including Daniel Funsch, MD; Michael Wasef, MD; Takashi Nakamura, MD; and several nurse practitioners — reviews intakes and conducts virtual consultations. Novi states that providers retain the authority to deny treatment for any reason consistent with their clinical judgment, including potential misuse risk.

The honest read on telehealth eligibility screening generally — Novi included — is that it's only as thorough as the patient's disclosure. The intake questionnaire format is well-suited to identifying named contraindications when patients accurately report family history and existing conditions. It is less able to identify subclinical issues that might emerge in an in-person physical examination. Novi's published telehealth consent acknowledges this — explicitly noting that telehealth providers rely primarily on patient-reported data rather than in-person physical exams.

For patients with uncertain medical histories, complex medication regimens, or known cardiovascular or endocrine concerns, the right diligence is to discuss the prospective treatment with an existing primary care or specialty physician before completing a telehealth intake. The telehealth platform isn't designed to replace that consultation — it's designed to handle the prescribing pathway after eligibility is reasonably established.

The Cancellation and Refund Terms — In Detail

This is where Novi's published terms become specific in ways that matter for tolerability decisions.

The 3-month minimum commitment is contractual. Per the published Terms of Service: the first month plus the next two months are charged at time of purchase and are non-refundable, unless a provider determines that treatment is not medically appropriate before any prescription is dispensed. After that point, the published terms do not provide a refund mechanism.

To stop further charges after the 3-month commitment is completed, cancellation must be submitted at least 15 days before the next monthly processing date. Cancellation can be made by emailing support@joinnovi.com or through the patient dashboard.

Once a prescription is dispensed or shipped, that prescription cannot be returned or refunded under any condition listed in the published terms. The terms further state: “False credit card disputes will be aggressively defended and customers who attempt to dispute charges to circumvent the 3-month commitment will be sent to collections and/or have further legal action pursued.”

What this means in practice for a patient experiencing significant side effects in month one of a 3-month commitment:

Communicating with the prescriber to discuss dose adjustment, alternative medications, or temporary holds is the available pathway within the platform. Discontinuing the medication doesn't, by itself, end the financial commitment to the remaining months. Whether and how Novi's clinical team handles tolerability-based discontinuation requests in practice — including whether unused future months can be paused, refunded, or applied to a different course — is a question prospective patients should clarify with support@joinnovi.com before signing up. The published terms describe a strict commitment structure; the operational practice may include flexibility that isn't documented.

For the financial breakdown of what the 3-month commitment looks like in dollar terms, see our Novi cost analysis.

The Telehealth Consent Document and What It Acknowledges

Novi's published Medical Consent describes the limitations of telehealth in clear language. It acknowledges that, in rare cases, transmitted information may be insufficient for appropriate medical decision-making, that delays in evaluation could occur due to equipment failures, that security protocols could fail in very rare instances, and that lack of complete medical records may result in adverse drug interactions or judgment errors.

The consent also confirms that the platform does not replace emergency medical services. The Terms of Service repeat this in capital letters: “WE ARE NOT A REPLACEMENT FOR EMERGENCY MEDICAL SERVICES. IF YOU HAVE A MEDICAL EMERGENCY SEEK EMERGENCY MEDICAL CARE IMMEDIATELY IN-PERSON OR DIAL 911 OR YOUR LOCAL EMERGENCY NUMBER.”

This is standard for compliant telehealth platforms and reflects the actual scope of what telehealth can and cannot do. It also points to a real evaluation criterion: the right candidate for any compounded-GLP-1 telehealth program is a patient whose general health status is well-characterized through existing in-person medical care, who can independently recognize when symptoms exceed the telehealth scope, and who has appropriate in-person medical resources for situations that arise outside that scope.

Insurance, Medical Records, and HIPAA

Novi states that all prescriptions are cash-pay. Insurance reimbursement may be available for branded GLP-1 medications, but compounded options are positioned as the affordable cash-pay alternative. The platform is not enrolled as a participating provider in Medicare, Medicaid, or other federal or state healthcare programs.

Patient information is treated under HIPAA. Novi's Notice of Privacy Practices describes standard HIPAA-permissible uses for treatment, payment, and healthcare operations. Patients have the right to access their records, request amendments, request restrictions on disclosures, and file complaints with the platform's Compliance and Privacy Officer or with the U.S. Department of Health and Human Services Office for Civil Rights. The HIPAA contact line published in Novi's privacy practices is (844) 357-3601.

SMS messaging is opt-in. Per the published policy, mobile information is not shared with third parties for advertising purposes. Patients can opt out of SMS at any time by replying STOP.

The Honest-Broker Read on Novi's Safety and Cancellation Mechanics

Novi's published clinical screening process is consistent with standard telehealth-prescribing operations for the compounded GLP-1 category. The platform's terms are transparent about what telehealth can and cannot do. The contraindication screening relies on patient self-disclosure, which is true for the entire telehealth category.

The cancellation and refund mechanics are stricter than what some patients might assume from the marketing. The “cancel anytime” framing on the homepage is technically accurate — the cancellation request can be submitted anytime — but the contractual obligation to three months of payments isn't reversible based on tolerability or response to the medication. That structure isn't unusual in the compounded-GLP-1 telehealth category, but it should be understood explicitly before signing up.

For prospective Novi patients with a clean medical history and reasonable comfort with the GLP-1 side effect profile: the platform's clinical and policy structure is functional, transparent, and within category norms. For patients whose tolerance for side effects is uncertain, or who would want a one-month trial before committing financially, Novi's structure isn't a fit. We compare Novi's policies head-to-head with other compounded-GLP-1 platforms in our Novi vs SynergyRx vs TeleHealth Med comparison.

For the full editorial breakdown of what to evaluate before any compounded-GLP-1 commitment, see the core Novi review.

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Please note: This is a regulatory and clinical analysis for educational purposes. It is not medical advice. GLP-1 medications — both compounded and FDA-approved finished products — are prescription only and require evaluation by a licensed clinician. Compounded medications are not FDA-approved finished drugs.

The most important question for anyone considering a compounded GLP-1 telehealth program in May 2026 isn't about results. It's about supply chain.

Two days before this article was written — on April 30, 2026 — the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The proposal carries direct implications for how platforms like Novi can source the medications they prescribe. To understand what that means, the regulatory categories themselves need to be clear.

This article walks through the actual differences between compounded and brand-name GLP-1 medications, what 503A and 503B compounding mean, where Novi sits inside that framework, and how to ask the right diligence questions before committing to any compounded-GLP-1 telehealth program.

Brand-Name GLP-1 Medications: The FDA-Approved Finished Drugs

Four brand-name GLP-1 receptor agonist products dominate the conversation. Semaglutide is sold as Ozempic for type 2 diabetes management and as Wegovy for chronic weight management — both manufactured by Novo Nordisk. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management — both manufactured by Eli Lilly. Liraglutide is sold as Victoza (diabetes) and Saxenda (weight management) by Novo Nordisk.

These are FDA-approved finished drug products. The FDA reviewed and approved each specific formulation, dose strength, delivery device, and indication based on the manufacturer's clinical trial data. Manufacturing is conducted under FDA Current Good Manufacturing Practice (CGMP) regulations with full supply chain oversight.

The peer-reviewed clinical trial evidence for these products is substantial. The STEP trial program for semaglutide 2.4 mg reported average body weight reductions in the range of approximately 14.9% over 68 weeks in adults without type 2 diabetes. The SURMOUNT trials for tirzepatide 15 mg reported approximately 20.9% over 72 weeks. A 2026 systematic review across 22 randomized controlled trials with 41,757 individuals confirmed both molecules as effective for weight loss in patients with and without diabetes.

The trade-off is price. Cash-pay list prices for Wegovy and Zepbound have run above $1,000 per month at retail in the United States. Insurance coverage varies widely — many plans don't cover GLP-1 medications for weight management, only for diabetes. That gap is what created demand for the compounded category.

Compounded GLP-1 Medications: A Different Regulatory Framework

Compounding is the practice of preparing customized medications by combining or altering pharmaceutical ingredients to meet individual patient needs. It exists for legitimate reasons — patients with allergies to standard formulations, dose strengths not commercially available, alternative delivery routes, or pediatric customization.

The Federal Food, Drug, and Cosmetic Act recognizes two compounding categories.

Section 503A covers state-licensed pharmacies that compound patient-specific prescriptions. The model is typically: one prescription, one patient, one formulation. 503A operates primarily under state board of pharmacy regulation, not direct FDA premarket approval. The compounded product itself isn't FDA-approved as a finished drug — it's compounded based on a specific patient prescription.

Section 503B covers outsourcing facilities — larger-scale compounders that register with the FDA and operate under federal oversight. 503B facilities can produce compounded medications in batch quantity, including for office stock and provider distribution. They operate under requirements closer to (but not equivalent to) full pharmaceutical manufacturing.

The legal pathway for either category to compound copies of an FDA-approved drug is narrow. Generally, a 503A or 503B compounder may produce a copy only when (a) the FDA-approved product appears on the FDA's drug shortage list, or (b) for 503B specifically, the bulk active pharmaceutical ingredient is on the FDA's 503B bulks list, indicating clinical need.

For semaglutide and tirzepatide, both pathways were active during the 2022–2024 shortage period. Demand outstripped Novo Nordisk and Eli Lilly's manufacturing capacity. The FDA placed both molecules on the shortage list. Compounding pharmacies — both 503A and 503B — moved to fill the gap, often at $150 to $300 per month versus $1,000+ for the brand-name products. The scale was significant. By October 2025, IQVIA reporting indicated more than 80% of compounded semaglutide and tirzepatide prescriptions included supplemental ingredients (B vitamins, levocarnitine), which compounders cited as evidence of customization beyond simple copying — and which the FDA viewed with skepticism.

What Changed: The Wind-Down and the April 30, 2026 Proposal

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Both removals triggered phased enforcement deadlines for compounders to wind down operations. The Outsourcing Facilities Association filed federal lawsuits challenging both determinations. Courts denied preliminary injunctions in both cases. The wind-down deadlines held.

That left one remaining structural question for 503B compounding of these GLP-1 molecules: would the FDA add semaglutide, tirzepatide, or liraglutide to the 503B bulks list, which would have created an alternative legal pathway for ongoing 503B compounding regardless of shortage status?

The April 30, 2026 proposal answers that question. The FDA explicitly determined there is no clinical need to include any of the three molecules on the 503B bulks list. Per FDA Commissioner Marty Makary, MD, MPH, in the agency's announcement: “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.”

The proposal is open for public comment through June 29, 2026, after which the FDA will consider submissions before issuing a final determination. If finalized, it formally closes the 503B pathway for bulk compounding of semaglutide, tirzepatide, and liraglutide — even in the event of a future shortage designation.

Patient safety data played a role. As of early 2025, the FDA had received over 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide. Many involved dosing errors from patients self-administering incorrect amounts from multidose vials, with some requiring hospitalization. Concerns about counterfeit products entering the market through online channels reinforced the agency's enforcement posture. We cover the side effect profile and Novi's specific patient safety mechanics in our side effects and cancellation policy review.

What This Means for 503A Compounding

The April 30 proposal targets 503B specifically. The 503A pathway — patient-specific compounding by state-licensed pharmacies — operates under a different statutory framework that doesn't depend on the 503B bulks list. As of early May 2026, 503A pharmacies continue to compound patient-specific prescriptions for semaglutide, tirzepatide, and liraglutide where state law permits and where the prescribing relationship is legitimate.

That said, the 503A pathway has its own constraints. 503A compounding is supposed to be patient-specific — produced for an individual patient on the basis of a specific prescription, not produced in bulk for office stock or undifferentiated patient populations. The “essentially a copy” doctrine — under which a compounder cannot legally produce a near-duplicate of an available FDA-approved drug — applies to both pathways. The line between legitimate 503A compounding and impermissible mass production is one the FDA, state pharmacy boards, and courts have been actively defining.

The practical implication: telehealth platforms historically supplied by 503B outsourcing facilities have already begun adapting. Some have shifted toward 503A pharmacy partnerships. Others have begun pivoting toward brand-name medication access at brand-name prices. Some have announced exits from the compounded GLP-1 category entirely.

Where Novi Sits in This Framework

Novi's published terms describe sourcing from “trusted, licensed U.S. pharmacies” and reference “pharmacy network providers” without naming specific partners or specifying 503A versus 503B status. The platform's marketing emphasizes that medications are “authentic and sourced from trusted, licensed U.S. pharmacies,” with quality and safety standards.

That's a transparency gap that prospective patients can close by asking. Specific questions that yield useful answers:

Are Novi's pharmacy partners 503A state-licensed pharmacies, 503B outsourcing facilities, or both? If 503B, are those facilities adapting their sourcing in light of the April 30, 2026 proposal? Does the platform plan to continue compounded sourcing if and when the proposal is finalized? Will pricing change if sourcing shifts? Are certificates of analysis (sterility, endotoxin, potency) available on request? Is the active ingredient semaglutide free base or sodium versus semaglutide acetate? (Acetate forms are not used in FDA-approved finished products and have been associated with quality concerns.)

These questions are answerable by support@joinnovi.com. The platforms that answer them clearly are differentiating themselves. The platforms that don't, in the current regulatory environment, are accepting transparency risk that prospective patients should weigh in their decision. Our broader analysis of how Novi compares against other platforms on disclosure and pharmacy network transparency is in the Novi vs SynergyRx vs TeleHealth Med comparison.

The Clinical Equivalence Question

A common claim in compounded-GLP-1 marketing — including some of Novi's marketing language — is that compounded versions contain “the same active ingredient as” the brand-name drug. This is technically defensible at the chemical level when the bulk API is genuine semaglutide free base or sodium produced to USP standards. It is not the same statement as saying the products are clinically equivalent.

FDA-approved finished products go through bioequivalence and clinical trial documentation that compounded versions don't. The finished formulation — the inactive ingredients, the buffer system, the delivery device, the manufacturing controls — affects pharmacokinetics, stability, and reproducibility. Two products with the same active ingredient at the same nominal dose may not deliver identical clinical outcomes if the finished formulation differs materially.

The published peer-reviewed efficacy data for semaglutide and tirzepatide — the 14.9% and 20.9% body-weight-reduction figures from the STEP and SURMOUNT trials — was generated using brand-name FDA-approved finished products. Whether and to what extent compounded versions deliver comparable outcomes hasn't been studied in equivalent trials. Treat outcome expectations on compounded versions as uncertain in a way they aren't with brand-name products.

For the broader pricing context that drives the choice between categories, see our Novi cost analysis.

What a Reasonable Decision Framework Looks Like

For a prospective patient evaluating compounded versus brand-name GLP-1 access through Novi or any similar platform, a reasonable evaluation framework includes:

The clinical fit. Whether GLP-1 therapy is medically appropriate, given BMI, comorbidities, contraindications, and goals. This is determined with a licensed clinician, not from a marketing page.

The regulatory fit. Whether the platform's pharmacy network operates under 503A or 503B, and whether the platform is positioned to adapt if the FDA proposal is finalized. Platforms that aren't transparent on this dimension carry more uncertainty than platforms that are.

The financial fit. Whether brand-name access through insurance is feasible (some plans cover Wegovy or Zepbound; many require prior authorization, BMI documentation, and step therapy). Whether brand-name cash-pay pricing is feasible. Whether the compounded-medication price point with a 3-month commitment is the right structure for the patient's situation.

The transparency fit. How the platform answers diligence questions. Whether certificates of analysis are available. Whether named pharmacy partners are disclosed.

The full picture of what to evaluate before signing up with Novi specifically is covered in our core Novi review.